Enlivex Receives Allocetra IND Clearance From The U.S. Food And Drug Administration For Treatment Of Patients with Advanced Solid Malignancies
November 28, 2022 08:00 ET | Enlivex Therapeutics Ltd
IND filing followed encouraging preclinical studies conducted in collaboration with Yale Cancer Center that showed a substantial, statistically significant survival benefit when Allocetra™ was...
GT Biopharma Presents Two Posters at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
November 10, 2022 15:15 ET | GT Biopharma, Inc.
Poster #1: Tri-specific killer engagers target natural killer cells towards mesotheliomaPoster #2: Enhancing NK cell function in the 'cold' tumor microenvironment of prostate cancer with a novel...
Enlivex Announces New Preclinical Data in Murine Mesothelioma Model Showing a Substantial Survival Benefit with Allocetra as Monotherapy and in Combination with Cisplatin at the ESMO Congress 2022
September 12, 2022 08:00 ET | Enlivex Therapeutics Ltd
Currently used cisplatin-based combination treatments have limited efficacy against mesothelioma, which is one of the deadliest solid cancers Combining cisplatin with Allocetra™ led to a...
CPI Logo-Color.png
Constellation Pharmaceuticals Presents Phase 1 Data for CPI-0209 at ASCO Annual Meeting
June 04, 2021 09:00 ET | Constellation Pharmaceuticals , Inc.
Pharmacodynamic data show comprehensive target engagement after treatment with CPI-0209 monotherapyOral, once-daily 350mg dose selected for Phase 2Enrollment of tumor-specific expansion cohorts is...
Momotaro Gene Logo.png
Momotaro-Gene Announces First Patient Dosed in Phase 2 Clinical Trial of MTG201 in Combination with Nivolumab in Patients with Relapsed Malignant Pleural Mesothelioma
September 11, 2019 07:30 ET | Momotaro-Gene
OKAYAMA, Japan, Sept. 11, 2019 (GLOBE NEWSWIRE) -- Momotaro-Gene, a clinical-stage biotherapeutics company developing novel gene therapies for the treatment of cancer, today announced the dosing of...
Harpoon_logo (002).jpg
Harpoon Therapeutics Doses First Patient with a Mesothelin-Targeting T cell Engager (HPN536) in Phase 1/2a Clinical Trial for Ovarian and Other Solid Tumor Cancers
April 18, 2019 07:30 ET | Harpoon Therapeutics
HPN536 is the second TriTAC T cell engager to enter clinical development from the Harpoon pipeline Trial initiated at Sarah Cannon Research Institute in Nashville, Tenn. - a leading drug development...
Mike Shepard
Attorney Michael Shepard named a 2018 Lawyer of the Year by Massachusetts Lawyers Weekly After Landmark Industry Verdict
January 29, 2019 10:52 ET | Shepard Law, P.C.
BOSTON, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Michael Shepard, founder of Shepard Law, one of the top asbestos personal injury law firms in Massachusetts, was selected by Massachusetts Lawyers Weekly as...
Jury Awards $6.8 Mil
Jury Awards $6.8 Million Verdict to Mesothelioma Victim’s Widow
October 02, 2017 09:50 ET | Thornton Law Firm
Boston, Massachusetts, Oct. 02, 2017 (GLOBE NEWSWIRE) -- A Superior Court jury in Boston returned a verdict of $6.8 million dollars against New England Insulation, a Canton company that distributed...
Mesothelioma Victim
Mesothelioma Victim Receives Record Asbestos Verdict in New England
September 21, 2017 11:56 ET | Thornton Law Firm
BOSTON, Mass., Sept. 21, 2017 (GLOBE NEWSWIRE) -- A Superior Court jury in Boston returned a verdict of $7.55 million dollars against New England Insulation, a Canton company that distributed and...
Selecta Biosciences Obtains License for Recombinant Immunotoxin LMB-100 from National Cancer Institute (NCI) for Pancreatic Cancer, Mesothelioma and Other Cancers
May 02, 2017 08:00 ET | Selecta Biosciences
NCI Currently Conducting Clinical Trials with LMB-100LMB-100 and SVP-Rapamycin Combination Treatment Enhances Anti-Tumor Activity in Preclinical Models Selecta and NCI in Discussions Regarding Phase...